製品番号: HY-15457

Triciribine

(別名: API-2; NSC 154020; TCN)

23 Cited Publications

カスタマーレビュー

Based on 23 publication(s) in Google Scholar

Triciribine is a DNA synthesis inhibitor, also inhibits Akt and HIV-1/2 with IC₅₀ of 130 nM, and 0.02-0.46 μM, respectively.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 98.62%
CAS 番号: 35943-35-2
分子式: C₁₃H₁₆N₆O₄
分子量:320.30

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Triciribine 構造式

CAS 番号: 35943-35-2

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- 体内実験
- 臨床実験
化学情報
Publications (23)
溶剤 & 溶解度
- 体外
- 体内
プロトコル
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

Triciribine is a DNA synthesis inhibitor, also inhibits Akt and HIV-1/2 with IC₅₀ of 130 nM, and 0.02-0.46 μM, respectively.

IC₅₀ & Target^[1]^[2]^{[3]

DNA synthesis

HIV-1
0.02-0.46 μM (IC₅₀)

HIV-2
0.02-0.46 μM (IC₅₀)

Akt
130 nM (IC₅₀, cell assay)

DNA/RNA Synthesis アイソフォーム固有の製品をすべて表示 :

RNASE L

DNA Polymerases

RNA Polymerases

Helicases

DNA Ligase

Nudix hydrolas

Akt アイソフォーム固有の製品をすべて表示 :

Akt

Akt1

Akt2

Akt3

HIV アイソフォーム固有の製品をすべて表示 :

HIV

HIV-1

HIV-2}

Cellular Effect

Cell Line	Type	Value	Description	References
184B5	GI₅₀	16.96 μM Compound: 5	Cytotoxicity against human 184B5 cells at 20 uM chloroquine by SRB assay Cytotoxicity against human 184B5 cells at 20 uM chloroquine by SRB assay	[PMID: 18691894]
184B5	GI₅₀	34 μM Compound: 5	Cytotoxicity against human 184B5 cells at 10 uM chloroquine by SRB assay Cytotoxicity against human 184B5 cells at 10 uM chloroquine by SRB assay	[PMID: 18691894]
184B5	GI₅₀	40 μM Compound: 5	Cytotoxicity against human 184B5 cells by SRB assay Cytotoxicity against human 184B5 cells by SRB assay	[PMID: 18691894]
AA5	IC₅₀	<0.17 μM Compound: TCN	Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 0.78 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 0.78 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
AA5	IC₅₀	<0.17 μM Compound: TCN	Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 1.56 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 1.56 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
AA5	IC₅₀	<0.17 μM Compound: TCN	Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 3.13 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 3.13 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
AA5	IC₅₀	>53.1 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 0.78 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 0.78 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA	[PMID: 20086149]
AA5	IC₅₀	>53.1 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 1.56 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 1.56 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA	[PMID: 20086149]
AA5	IC₅₀	>53.1 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 3.13 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 3.13 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA	[PMID: 20086149]
AA5	IC₅₀	>53.1 μM Compound: TCN	Cytotoxicity against human AA5 cells by MTS assay Cytotoxicity against human AA5 cells by MTS assay	[PMID: 20086149]
ACH-2 cell line	CC₅₀	0.01 μM Compound: TCN	Cytotoxicity against human ACH2 cells infected with latent Human immunodeficiency virus 1 by MTS assay Cytotoxicity against human ACH2 cells infected with latent Human immunodeficiency virus 1 by MTS assay	[PMID: 20086149]
ACH-2 cell line	CC₅₀	0.01 μM Compound: TCN	Cytotoxicity against human ACH2 cells infected with latent Human immunodeficiency virus 1 by MTS assay in presence of tumor necrosis factor alpha Cytotoxicity against human ACH2 cells infected with latent Human immunodeficiency virus 1 by MTS assay in presence of tumor necrosis factor alpha	[PMID: 20086149]
ACH-2 cell line	IC₅₀	0.15 μM Compound: TCN	Antiviral activity against 5 x 10'3 cells/well Human immunodeficiency virus 1 infected in human ACH2 cells assessed as inhibition of viral Reverse transcriptase after 3 days by [3H]TTP incorporation assay in presence of 5 ng/ml tumor necrosis factor alpha Antiviral activity against 5 x 10'3 cells/well Human immunodeficiency virus 1 infected in human ACH2 cells assessed as inhibition of viral Reverse transcriptase after 3 days by [3H]TTP incorporation assay in presence of 5 ng/ml tumor necrosis factor alpha	[PMID: 20086149]
BSC-1	IC₅₀	23 μM Compound: TCN	Antiviral activity against HSV-1 was determined using BSC-1 cells by an enzyme-linked immunosorbent assay (ELISA) Antiviral activity against HSV-1 was determined using BSC-1 cells by an enzyme-linked immunosorbent assay (ELISA)	[PMID: 10882373]
BSC-1	IC₅₀	23 μM Compound: Triciribine(TCN)	Antiviral activity was tested using an enzyme-linked immunosorbent assay (ELISA) to detect HSV-1 (herpes simplex virus type 1) using BSC-1 cells Antiviral activity was tested using an enzyme-linked immunosorbent assay (ELISA) to detect HSV-1 (herpes simplex virus type 1) using BSC-1 cells	[PMID: 10882371]
CEM-SS	CC₅₀	77.3 μM Compound: TCN	Cytotoxicity against human CEM-SS cells infected with Human immunodeficiency virus 2 ROD by MTS assay Cytotoxicity against human CEM-SS cells infected with Human immunodeficiency virus 2 ROD by MTS assay	[PMID: 20086149]
CEM-SS	CC₅₀	85.8 μM Compound: TCN	Cytotoxicity against human CEM-SS cells by MTS assay Cytotoxicity against human CEM-SS cells by MTS assay	[PMID: 20086149]
CEM-SS	CC₅₀	88.5 μM Compound: TCN	Cytotoxicity against human CEM-SS cells infected with Human immunodeficiency virus 1 SK1 by MTS assay Cytotoxicity against human CEM-SS cells infected with Human immunodeficiency virus 1 SK1 by MTS assay	[PMID: 20086149]
CEM-SS	IC₅₀	<0.01 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 0.78 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 0.78 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA	[PMID: 20086149]
CEM-SS	IC₅₀	>10 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 harboring plasmid TAK-1 infected in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 harboring plasmid TAK-1 infected in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
CEM-SS	IC₅₀	>10 μM Compound: TCN	Ratio of IC50 for Human immunodeficiency virus 1 H10 infected in CEM-SS cells to IC50 for Human immunodeficiency virus 1 3B infected in CEM-SS cells Ratio of IC50 for Human immunodeficiency virus 1 H10 infected in CEM-SS cells to IC50 for Human immunodeficiency virus 1 3B infected in CEM-SS cells	[PMID: 20086149]
CEM-SS	IC₅₀	>100 μM Compound: TCN	Visual cytotoxicity was scored on CEM-SS cells Visual cytotoxicity was scored on CEM-SS cells	[PMID: 10882373]
CEM-SS	IC₅₀	>100 μM Compound: Triciribine(TCN)	Tested for visual cytotoxicity on uninfected CEM-SS cells Tested for visual cytotoxicity on uninfected CEM-SS cells	[PMID: 10882371]
CEM-SS	IC₅₀	>3.13 μM Compound: TCN	Cytotoxicity against human CEM-SS cells by MTS assay Cytotoxicity against human CEM-SS cells by MTS assay	[PMID: 20086149]
CEM-SS	IC₅₀	>30 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 A12 harboring Tyr127His, Asp174Asn and Arg178Lys mutations in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 A12 harboring Tyr127His, Asp174Asn and Arg178Lys mutations in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
CEM-SS	IC₅₀	>30 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 H10 harboring Tyr127His, Gly140Glu, Glu149Lys, Asp174Asn and Arg178Lys mutations in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporat Antiviral activity against Human immunodeficiency virus 1 H10 harboring Tyr127His, Gly140Glu, Glu149Lys, Asp174Asn and Arg178Lys mutations in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporat	[PMID: 20086149]
CEM-SS	IC₅₀	0.04 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 3B expressing nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 3B expressing nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
CEM-SS	IC₅₀	0.08 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 0.78 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 0.78 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
CEM-SS	IC₅₀	0.13 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 SK1 infected in human CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 SK1 infected in human CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
CEM-SS	IC₅₀	0.19 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 1.56 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 1.56 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA	[PMID: 20086149]
CEM-SS	IC₅₀	0.2 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 harboring plasmid NL4-3 infected in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 harboring plasmid NL4-3 infected in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
CEM-SS	IC₅₀	0.24 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 3.13 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 3.13 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA	[PMID: 20086149]
CEM-SS	IC₅₀	0.29 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 1.56 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 1.56 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
CEM-SS	IC₅₀	0.3 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 3.13 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 3.13 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
CEM-SS	IC₅₀	0.33 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 D1 harboring Tyr127His mutation in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 D1 harboring Tyr127His mutation in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
CEM-SS	IC₅₀	0.5 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 A7 harboring Tyr127His mutation in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 A7 harboring Tyr127His mutation in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
CEM-SS	IC₅₀	1.4 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 2 ROD infected in human CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 2 ROD infected in human CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
H9	CC₅₀	19.6 μM Compound: TCN	Cytotoxicity against human H9 cells by MTS assay Cytotoxicity against human H9 cells by MTS assay	[PMID: 20086149]
H9	IC₅₀	<0.1 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 12.5 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 12.5 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA	[PMID: 20086149]
H9	IC₅₀	<0.1 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 12.5 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 12.5 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
H9	IC₅₀	<0.1 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 25 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 25 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
H9	IC₅₀	<0.1 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 6.25 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 6.25 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA	[PMID: 20086149]
H9	IC₅₀	<0.1 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 6.25 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 6.25 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
H9	IC₅₀	>31.3 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 25 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 25 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA	[PMID: 20086149]
H9	IC₅₀	>31.3 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 50 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 50 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA	[PMID: 20086149]
H9	IC₅₀	0.036 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 SK1 infected in human H9 cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 SK1 infected in human H9 cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
H9	IC₅₀	1.53 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 50 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 50 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
H9	IC₅₀	16.3 μM Compound: TCN	Cytotoxicity against human H9 cells by MTS assay Cytotoxicity against human H9 cells by MTS assay	[PMID: 20086149]
HFF	IC₅₀	100 μM Compound: 8	Visual cytotoxicity was determined in uninfected HFF cells using plaque assay Visual cytotoxicity was determined in uninfected HFF cells using plaque assay	[PMID: 15916436]
HFF	IC₅₀	100 μM Compound: TCN	Visual cytotoxicity was scored on uninfected HFF cells Visual cytotoxicity was scored on uninfected HFF cells	[PMID: 10882373]
HFF	IC₅₀	100 μM Compound: Triciribine(TCN)	Tested for visual cytotoxicity on uninfected HFF cells Tested for visual cytotoxicity on uninfected HFF cells	[PMID: 10882371]
HFF	IC₅₀	2.5 μM Compound: TCN	Antiviral activity against HCMV was determined by plaque reduction assay using HFF cells Antiviral activity against HCMV was determined by plaque reduction assay using HFF cells	[PMID: 10882373]
HFF	IC₅₀	2.5 μM Compound: Triciribine(TCN)	HCMV plaque assay was performed using HFF cells and effect was calculated as a percentage of reduction in number of plaques HCMV plaque assay was performed using HFF cells and effect was calculated as a percentage of reduction in number of plaques	[PMID: 10882371]
Huh-7	CC₅₀	>300 μM Compound: 3	Cytotoxicity using HCV replicon assay Cytotoxicity using HCV replicon assay	[PMID: 15177464]
Huh-7	EC₅₀	2 μM Compound: 3	Compound was tested for its ability to inhibit hepatitis C viral RNA replication in Huh-7 cells (human hepatoma cells) Compound was tested for its ability to inhibit hepatitis C viral RNA replication in Huh-7 cells (human hepatoma cells)	[PMID: 15177464]
KB	IC₅₀	>100 μM Compound: TCN	Cytotoxicity measured as Inhibition of KB cell growth was assessed. Cytotoxicity measured as Inhibition of KB cell growth was assessed.	[PMID: 10882373]
KB	IC₅₀	>100 μM Compound: Triciribine(TCN)	Inhibition of KB cell growth was assessed Inhibition of KB cell growth was assessed	[PMID: 10882371]
KB	IC₅₀	100 μM Compound: 8	Inhibitory concentration was determined for KB cell growth Inhibitory concentration was determined for KB cell growth	[PMID: 15916436]
L1210	IC₅₀	0.035 μM Compound: Triciribine(TCN)	Tested in vitro for cytotoxicity against murine L1210 leukemic cells Tested in vitro for cytotoxicity against murine L1210 leukemic cells	[PMID: 10882371]
MCF7	GI₅₀	0.05 μM Compound: 5	Cytotoxicity against human MCF7 cells in presence of 20 uM chloroquine by SRB assay Cytotoxicity against human MCF7 cells in presence of 20 uM chloroquine by SRB assay	[PMID: 18691894]
MCF7	GI₅₀	0.56 μM Compound: 5	Cytotoxicity against human MCF7 cells in presence of 10 uM chloroquine by SRB assay Cytotoxicity against human MCF7 cells in presence of 10 uM chloroquine by SRB assay	[PMID: 18691894]
MCF7	GI₅₀	3.64 μM Compound: 5	Cytotoxicity against human MCF7 cells by SRB assay Cytotoxicity against human MCF7 cells by SRB assay	[PMID: 18691894]
MDA-MB-231	GI₅₀	0.69 μM Compound: 5	Cytotoxicity against human MDA-MB-231 cells in presence of 20 uM chloroquine by SRB assay Cytotoxicity against human MDA-MB-231 cells in presence of 20 uM chloroquine by SRB assay	[PMID: 18691894]
MDA-MB-231	GI₅₀	37 μM Compound: 5	Cytotoxicity against human MDA-MB-231 cells in presence of 10 uM chloroquine by SRB assay Cytotoxicity against human MDA-MB-231 cells in presence of 10 uM chloroquine by SRB assay	[PMID: 18691894]
MDA-MB-231	GI₅₀	50.15 μM Compound: 5	Cytotoxicity against human MDA-MB-231 cells by SRB assay Cytotoxicity against human MDA-MB-231 cells by SRB assay	[PMID: 18691894]
MDA-MB-468	GI₅₀	10.29 μM Compound: 5	Cytotoxicity against human MDA-MB-468 cells in presence of 20 uM chloroquine by SRB assay Cytotoxicity against human MDA-MB-468 cells in presence of 20 uM chloroquine by SRB assay	[PMID: 18691894]
MDA-MB-468	GI₅₀	20.45 μM Compound: 5	Cytotoxicity against human MDA-MB-468 cells in presence of 10 uM chloroquine by SRB assay Cytotoxicity against human MDA-MB-468 cells in presence of 10 uM chloroquine by SRB assay	[PMID: 18691894]
MDA-MB-468	GI₅₀	43.53 μM Compound: 5	Cytotoxicity against human MDA-MB-468 cells by SRB assay Cytotoxicity against human MDA-MB-468 cells by SRB assay	[PMID: 18691894]
U1	CC₅₀	0.28 μM Compound: TCN	Cytotoxicity against human U1 cells infected with latent Human immunodeficiency virus 1 by MTS assay Cytotoxicity against human U1 cells infected with latent Human immunodeficiency virus 1 by MTS assay	[PMID: 20086149]
U1	CC₅₀	0.28 μM Compound: TCN	Cytotoxicity against human U1 cells infected with latent Human immunodeficiency virus 1 by MTS assay in presence of tumor necrosis factor alpha Cytotoxicity against human U1 cells infected with latent Human immunodeficiency virus 1 by MTS assay in presence of tumor necrosis factor alpha	[PMID: 20086149]
U1	IC₅₀	0.23 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 infected in human U1 cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 infected in human U1 cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]

体外実験

The nucleoside analog Triciribine (TCN) is a purine analog which is initially shown to inhibit DNA synthesis. Triciribine selectively inhibits the phosphorylation and activation of all three Akt isoforms. At a concentration of 10 μM Triciribine Akt phosphorylation is inhibited at both Thr308 and Ser473. Triciribine effectively inhibits the phosphorylation and consequently the catalytic activity of Akt in PC-3 cells^[1]. The Akt inhibitor Triciribine (TCN) does not effectively inhibit the human cell line U87MG but inhibits other astrocytoma cell lines in a grade-dependent manner. The WHO II K1861-10 line is incompletely inhibited (69% maximum inhibition) with a GI₅₀ value of 1.7 μM for Triciribine. Triciribine exhibits maximum growth inhibition around 1-10 μM and inhibits phosphorylation of Akt, as well as downstream p70S6K, to basal levels at 100 μM (IC₅₀=130 nM) in KR158 cells^[2]. Triciribine (TCN) is a novel tricyclic compound with known antitumor activity. Using a syncytial plaque assay, Triciribine is active against HIV-1 at 0.01-0.02 μM. Using a microtiter XTT assay, Triciribine is active against a panel of HIV-1 and HIV-2 strains at IC₅₀ values ranging from 0.02 to 0.46 μM^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Triciribine (TCBN) treatment, administered for 7 days after 14 days of hypoxia until 21 days of hypoxia is reached, reversed the vascular thickening as shown by immunohistochemistry and Western analyses. On the other hand, Rapamycin treatment did not prevent hypoxia-induced pulmonary alveolar haemorrhage and congestion. Triciribine partially inhibits progressive pruning of the vasculature^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

臨床実験

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

化学情報

CAS 番号 35943-35-2
性状 Solid
分子量 320.30
分子式 C₁₃H₁₆N₆O₄
Color Light yellow to khaki
SMILES

OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N2C3=NC=NC4=C3C(C(N)=NN4C)=C2
別名

API-2; NSC 154020; TCN
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (23)

All WB

Sort by:

Journal Impact Factor

Science

The target landscape of clinical kinase drugs. [Abstract]

2017 Dec 1;358(6367):eaan4368. PMID: 29191878
Sci Transl Med

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]

2018 Jul 18;10(450):eaaq1093. PMID: 30021885
Small

Intranasal Zinc Oxide Nanoparticles Induce Neuronal PANoptosis via Microglial Pathway. [Abstract]

2025 Mar;21(12):e2408139. PMID: 40012250
Stem Cell Res Ther

TNFα and IFNγ rapidly activate PI3K-AKT signaling to drive glycolysis that confers mesenchymal stem cells enhanced anti-inflammatory property. [Abstract]

2022 Oct 4;13(1):491. PMID: 36195887
Stem Cell Res Ther

Extracellular matrix stiffness controls osteogenic differentiation of mesenchymal stem cells mediated by integrin α5. [Abstract]

2018 Mar 1;9(1):52. PMID: 29490668

Triciribine purchased from MedChemExpress. Usage Cited in: Stem Cell Res Ther. 2018 Mar 1;9(1):52. [Abstract]

Signaling protein expression detected by western blotting and quantified by densitometry with or without Triciribine.
Oncoimmunology

Ex vivo AKT-inhibition facilitates generation of polyfunctional stem cell memory-like CD8+ T cells for adoptive immunotherapy. [Abstract]

2018 Aug 6;7(10):e1488565. PMID: 30288356
EMBO Rep

Time required for commitment to T cell proliferation depends on TCR affinity and cytokine response. [Abstract]

2023 Jan 9;24(1):e54969. PMID: 36327141
Front Pharmacol

Shen-Yuan-Dan Capsule Attenuates Atherosclerosis and Foam Cell Formation by Enhancing Autophagy and Inhibiting the PI3K/Akt/mTORC1 Signaling Pathway. [Abstract]

2019 May 31:10:603. PMID: 31214032
Mol Cancer Res

Novel metastasis suppressor PI3KC2β is mediated by mTORC1 signalling in breast cancer. [Abstract]

2025 May 13. PMID: 40358607
Int Immunopharmacol

Artesunate alleviates intestinal ischemia/reperfusion induced acute lung injury via up-regulating AKT and HO-1 signal pathway in mice. [Abstract]

2023 Sep:122:110571. PMID: 37441813
Int J Antimicrob Agents

Efficacy of antiretroviral compounds against Toxoplasma gondii in vitro. [Abstract]

2019 Dec;54(6):814-819. PMID: 31479744
J Cell Mol Med

Inactivation of CDK12 Enhances Mitochondrial Efficiency to Suppress DNA Damage. [Abstract]

2026 Apr;30(7):e71101. PMID: 41896195
J Cell Mol Med

Photobiomodulation therapy promotes the ATP-binding cassette transporter A1-dependent cholesterol efflux in macrophage to ameliorate atherosclerosis. [Abstract]

2021 Jun;25(11):5238-5249. PMID: 33951300
J Cell Mol Med

Recepteur d'origine nantais contributes to the development of endometriosis via promoting epithelial-mesenchymal transition of a endometrial epithelial cells. [Abstract]

2021 Feb;25(3):1601-1612. PMID: 33410267
J Mol Med (Berl)

Combination of PARP inhibitor and temozolomide to suppress chordoma progression. [Abstract]

2019 Aug;97(8):1183-1193. PMID: 31201471
Surgery

Emodin alleviates intestinal ischemia/reperfusion-induced lung injury by upregulating HO-1 expression via PI3K/AkT pathway. [Abstract]

2024 May 28:S0039-6060(24)00230-7. PMID: 38811326
PLoS One

The mTOR/Akt pathway is involved in regulating astrocyte growth and GLT-1 expression during cerebral ischemia-reperfusion. [Abstract]

2026 Jun 12;21(6):e0351107. PMID: 42284260
J Cardiovasc Pharmacol

Danhong Injection Attenuates High-Fat-Induced Atherosclerosis and Macrophage Lipid Accumulation by Regulating the PI3K/AKT Insulin Pathway. [Abstract]

2019 Aug;74(2):152-161. PMID: 31306371
Biochem Biophys Res Commun

3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) ameliorated dexamethasone induced hepatic gluconeogenesis through activation of Akt/FoxO1 pathway. [Abstract]

2017 Nov 4;493(1):286-290. PMID: 28911865

Triciribine purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2017 Nov 4;493(1):286-290. [Abstract]

API-2 apparently inhibits insulin induced phosphorylation of Akt S473 in a dose dependent manner.

Triciribine purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2017 Nov 4;493(1):286-290. [Abstract]

Inhibition of pAkt by API-2 effectively prevents K145 induced increasing phosphorylation of FoxO1 in response to insulin. API-2 also significantly reverses K145 suppressed PEPCK and G6Pase mRNA and protein expression.
Med Sci Monit

Brain-Derived Neurotrophic Factor Alleviates Ropivacaine-Induced Neuronal Damage by Enhancing the Akt Signaling Pathway. [Abstract]

2019 Dec 30;25:10154-10163. PMID: 31885368
Exp Brain Res

Upregulation of glutamate transporter 1 by mTOR/Akt pathway in astrocyte culture during oxygen-glucose deprivation and reoxygenation. [Abstract]

2023 Jan;241(1):201-209. PMID: 36436003
Oxid Med Cell Longev

Photobiomodulation Therapy Ameliorates Glutamatergic Dysfunction in Mice with Chronic Unpredictable Mild Stress-Induced Depression. [Abstract]

2021 Mar 29:2021:6678276. PMID: 33859781
Radboud University Nijmegen

2019 Oct.

溶剤 & 溶解度

体外:

DMSO : 100 mg/mL (312.21 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.1221 mL

15.6104 mL

31.2207 mL

5 mM

0.6244 mL

3.1221 mL

6.2441 mL

10 mM

0.3122 mL

1.5610 mL

3.1221 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (7.81 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (7.81 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (7.81 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

プロトコル

Cell Assay^[2]

The human SF295 and U87MG GBM lines and the mouse K1861-10, KR158, and KR130G astrocytoma lines are plated at a density of 2500 cells/100 µL complete media in 96-well plates. Mouse primary astrocytes are plated at 5000 cells/100 µL. Cells are treated in triplicate with serial dilutions of inhibitors (The inhibitors tested are PI-103, Triciribine and Rapamycin) ranging from µM to pM. Cell proliferation is measured after 3 days using the Alamar Blue assay on a Novostar plate reader. Values for 50% inhibitory concentration (IC₅₀) and 50% growth inhibitory concentration (GI₅₀) are calculated using standard procedures in GraphPad Prism v4 and Microsoft Excel^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[4]

Mice^[4]
Akt1^+/+ and Akt1^−/− mice are subjected to normoxia or hypoxia (10% O₂) for 7 and 14 days (n=2-6 mice per group). Noteworthy, high mortality is observed in Akt1^−/− mice exposed to hypoxia longer than 14-16 days. For pharmacological inhibition studies, Akt1^+/+ mice, subjected to normoxia or chronic hypoxia for 14 days, received daily i.p. injection of saline, Triciribine (0.5 mg/kg per day) or Rapamycin (1.5 mg/kg per day) for 7 days, and the total continuous exposure to hypoxia or normoxia is 21 days (n=6-8 mice per group). Pharmacological inhibitors are administered daily while the mice are maintained in the hypoxia chamber to minimize exposure to air and spontaneous reversal of pulmonary remodelling.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (284 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Dieterle A, et al. The Akt inhibitor triciribine sensitizes prostate carcinoma cells to TRAIL-induced apoptosis. Int J Cancer. 2009 Aug 15;125(4):932-41. [Content Brief]

[2]. Gürsel DB, et al. Control of proliferation in astrocytoma cells by the receptor tyrosine kinase/PI3K/AKT signaling axis and the use of PI-103 and TCN as potential anti-astrocytoma. Neuro Oncol. 2011 Jun;13(6):610-21 [Content Brief]

[3]. Kucera LS, et al. Activity of triciribine and triciribine-5'-monophosphate against human immunodeficiency virus types 1 and 2. AIDS Res Hum Retroviruses. 1993 Apr;9(4):307-14. [Content Brief]

[4]. Abdalla M, et al. The Akt inhibitor, triciribine, ameliorates chronic hypoxia-induced vascular pruning and TGFβ-induced pulmonary fibrosis. Br J Pharmacol. 2015 Aug;172(16):4173-88. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.1221 mL	15.6104 mL	31.2207 mL	78.0518 mL
	5 mM	0.6244 mL	3.1221 mL	6.2441 mL	15.6104 mL
	10 mM	0.3122 mL	1.5610 mL	3.1221 mL	7.8052 mL
	15 mM	0.2081 mL	1.0407 mL	2.0814 mL	5.2035 mL
	20 mM	0.1561 mL	0.7805 mL	1.5610 mL	3.9026 mL
	25 mM	0.1249 mL	0.6244 mL	1.2488 mL	3.1221 mL
	30 mM	0.1041 mL	0.5203 mL	1.0407 mL	2.6017 mL
	40 mM	0.0781 mL	0.3903 mL	0.7805 mL	1.9513 mL
	50 mM	0.0624 mL	0.3122 mL	0.6244 mL	1.5610 mL
	60 mM	0.0520 mL	0.2602 mL	0.5203 mL	1.3009 mL
	80 mM	0.0390 mL	0.1951 mL	0.3903 mL	0.9756 mL
	100 mM	0.0312 mL	0.1561 mL	0.3122 mL	0.7805 mL

Keywords

Triciribine

23 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Triciribine

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

Kinase Inhibitor Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Antiviral Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Anti-COVID-19 Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Mitochondrial Toxicity Compound Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Lactylation Compound Library

MedChemExpress（MCE）の使用を引用している文献 Triciribine

DNA/RNA Synthesis アイソフォーム固有の製品をすべて表示

Akt アイソフォーム固有の製品をすべて表示

HIV アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (23)

溶剤 & 溶解度

プロトコル

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Triciribine 関連分類

HY-15457 関連分類